Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

about

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

Item

http://www.wikidata.org/entity/Q45893661

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

@en

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

@nl

type

Item

label

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

@en

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

@nl

prefLabel

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

@en

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

@nl

P1476

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective.

@en

P2093

Chloe Brown

http://www.w3.org/2001/XMLSchema#string

Mohammad Ashraf Chaudhary

http://www.w3.org/2001/XMLSchema#string

Noemi Muszbek

http://www.w3.org/2001/XMLSchema#string

Rebekah H Borse

http://www.w3.org/2001/XMLSchema#string

Sumesh Kachroo

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab

Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation

Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis.

Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register.

Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.

Mortality among patients with ankylosing spondylitis after a single treatment course with x rays.

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE).

Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.

P2888

s40744-017-0083-1

P304

427-443

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40744-017-0083-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1091974440

http://www.w3.org/2001/XMLSchema#string

P698

28956301

http://www.w3.org/2001/XMLSchema#string

P932

5696295

http://www.w3.org/2001/XMLSchema#string